Insulin receptor substrate signaling controls cardiac energy metabolism and heart failure

Cathy A Guo and Shaodong Guo
Department of Nutrition and Food Science, College of Agriculture and Life Sciences, Texas A&M University, College Station, Texas, USA

Abstract
The heart is an insulin-dependent and energy-consuming organ in which insulin and nutritional signaling integrates to the regulation of cardiac metabolism, growth and survival. Heart failure is highly associated with insulin resistance, and heart failure patients suffer from the cardiac energy deficiency and structural and functional dysfunction. Chronic pathological conditions, such as obesity and type 2 diabetes mellitus, involve various mechanisms in promoting heart failure by remodeling metabolic pathways, modulating cardiac energetics and impairing cardiac contractility. Recent studies demonstrated that insulin receptor substrates 1 and 2 (IRS-1,-2) are major mediators of both insulin and insulin-like growth factor-1 (IGF-1) signaling responsible for myocardial energetics, structure, function and organismal survival. Importantly, the insulin receptor substrates (IRS) play an important role in the activation of the phosphatidylinositide-3-dependent kinase (PI-3K) that controls Akt and Foxo1 signaling cascade, regulating the mitochondrial function, cardiac energy metabolism and the renin–angiotensin system. Dysregulation of this branch in signaling cascades by insulin resistance in the heart through the endocrine system promotes heart failure, providing a novel mechanism for diabetic cardiomyopathy. Therefore, targeting this branch of IRS→PI-3K→Foxo1 signaling cascade and associated pathways may provide a fundamental strategy for the therapeutic and nutritional development in control of metabolic and cardiovascular diseases. In this review, we focus on insulin signaling and resistance in the heart and the role energetics play in cardiac metabolism, structure and function.

Introduction
Insulin resistance is the major underlying mechanism for metabolic and cardiovascular dysfunction in obesity and type 2 diabetes mellitus (T2D) (Qi 2016). T2D is a high-risk factor in promoting heart failure and its prevalence has risen at an alarming rate over the past few decades and two-thirds of patients with T2D have died from heart failure (Roger et al. 2011). Multiple factors implicate the pathogenesis of diabetes-associated cardiac dysfunction, including hyperglycemia, insulin resistance, hyperinsulinemia, hyperlipidemia, oxidative stresses and inflammation (Battiprolu et al. 2010). These factors can cause energy metabolism alteration, calcium mishandling, mitochondrial dysfunction, apoptosis and myocardial structural damage and functional loss (Battiprolu et al. 2010). All of the factors often interact with each other therefore making T2D a complex disease to treat. In the
early 1970s, the concept of diabetic cardiomyopathy was recognized on the basis of hyperglycemia-induced cardiac dysfunction, independent of hypertension and coronary artery diseases (Rubler et al. 1972). Over the past decades, insulin resistance is believed to be a primary contributor to metabolic and cardiovascular dysfunction and serves as a high-risk factor for organ damage in promotion of heart failure and death in patients with diabetes (Roger et al. 2011). Thus, exploring the mechanism of insulin action and resistance opens a new chapter to expand our knowledge of diabetic cardiomyopathy. In this review, we discuss the mechanisms of insulin in governing cardiac energetics, and update on how insulin resistance promotes cellular dysfunction at the molecular level with interacting signaling cascade involving in IRS-1, -2 and Foxo1 genes.

Cardiac insulin action and metabolic flexibility

Upon food intake of carbohydrates, fatty acids or proteins, pancreatic β-cells secrete insulin, the most important endocrine hormone in promoting anabolic metabolism in target tissues and maintaining a balance of glucose and lipids in the blood circulation (Bertrand et al. 2008, Riehle & Abel 2016). In addition to facilitating glucose uptake and energy storage as macromolecules, such as lipids in the adipose tissue, and glycogen and protein in the skeletal muscle and liver, insulin also targets the heart to control energy metabolism in support of cardiac growth and function.

In comparison with other tissues, the heart is unique in that it consumes about 10% of whole body energy expenditure for cardiac contraction and is capable of utilizing all classes of substrates as energy resources, including carbohydrate, lipids, amino acids and ketone bodies (Kolwicz et al. 2013). The cardiomyocytes generate ATP via the substrate phosphorylation in the cytoplasm, which plays a key role in the heart under ischemia. However, the cardiomyocytes generate the major amount of ATP via the oxidative phosphorylation in the mitochondria that maintain cardiac function in the presence of oxygen. A human heart produces and consumes 3.5–6 kg of ATP every day with a myocardial process so dependent on oxidative phosphorylation that the mitochondria occupy one-third of the cell volume in each cardiomyocyte (Kolwicz et al. 2013).

Insulin is a major regulator in cellular energetics and metabolism in cardiomyocytes (Fig. 1). During the postprandial state, insulin secretion stimulates glucose uptake and utilization and synthesis of macromolecules in the heart. Glucose provides a favored oxidized substrate and generates 60–70% of ATP, whereas fatty acid oxidation provides only 20% of ATP in the heart (Bertrand et al. 2008). During fasting states when insulin level decreases, counter energy hormones such as glucagon increase, activating the catabolic metabolism, including enhanced lipolysis in the adipose tissue and increased fatty acid influx to the heart. Under these conditions, fatty acid oxidation acts as a major substrate for ATP production in generating 60–70% ATP in the heart and is favored over glucose (20%) and lactate (10%). Under prolonged fasting conditions, ketone bodies and amino acids contribute to ATP generation by converting to the tricarboxylic acid cycle intermediates and acetyl-CoA (Bertrand et al. 2008, Kolwicz et al. 2013). The substrate preferences for ATP production during the transition between the postprandial and fasting state are tightly controlled by the availability of nutrients and hormones. According to Randle, glucose utilization suppresses lipid utilization and vice versa, a process mediated by the presence of insulin and its sensitivity to enhance glucose utilization and suppress fatty acid oxidation (Randle et al. 1963). Thus, fatty acid oxidation rate increases in the fasting condition when insulin levels are low. However, this metabolic flexibility or adaptive transition under normal conditions is largely impaired in the heart when exposed to metabolic and mechanic stresses, particularly under conditions such as insulin resistance and T2D.

Control of cardiac homeostasis by IRS-1 and IRS-2

The metabolic control by insulin is tightly coupled to the insulin signaling cascade (Fig. 2). Over the past a few years, creation of insulin receptor substrates (IRS) in genetically engineered mouse models has provided major breakthroughs in our understanding of insulin-dependent control in cardiac energy metabolism and homeostasis, particularly for the role of protein kinase Akt (Guo 2014). Through previous experimentations and evidence, mice lacking the insulin receptor in the heart were born with reduced heart size and mitochondrial dysfunction, reflecting the key role of insulin receptor signaling in the regulation of postnatal cardiac size and substrate utilization (Belke et al. 2002). To investigate the role of cardiac insulin signaling, we generated H-DKO mice with heart-specific deletion of both IRS-1 and IRS-2 genes using

http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-16-0679
© 2017 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
the Cre/loxP genetic approach. The mice all developed dilated cardiomyopathy and males died of heart failure at the age of 6–9 weeks with cardiac energetic deficiency, mitochondrial dysfunction, myocardial structural damage and contractile functional loss (Qi et al. 2013, Riehle et al. 2013). These studies revealed novel findings of insulin action in control of cardiac growth, homeostasis and survival. Thus, we proposed that suppression of IRS-1 and IRS-2 may serve as a fundamental mechanism in cardiac insulin resistance and associated heart failure (Qi et al. 2013).

Insulin is known to activate both Raf→MAP kinase and PI-3K→Akt kinase signaling cascades, similar to that of IGF-1 and its receptor (IGF-1R), which shares high
Activated IR or IGF-1R directly phosphorylates tyrosine residues on several substrates including IRS-1,-2,-3,-4, Shc, Grb-2-associated protein (Gab1), Dock1, Cbl and APS adaptor proteins, subsequently providing specific docking sites for other signaling proteins in activating downstream protein kinases (White 2003). Mice lacking both IR and IGF-1-R in the heart displayed similar cardiac phenotype to that of H-DKO mice, in which elimination of PI-3K and Akt activity in cardiomyocytes contributed to cardiac failure and animal death (Laustsen et al. 2007, Qi et al. 2013). These studies revealed a fundamental mechanism for endogenous kinase activation of PI-3K and Akt that is entirely dependent on IRS-1 and -2 or insulin and IGF-1 in the heart.

Many other growth factors, such as VEGF and PDGF, are capable of activating PI-3K and Akt in cells (Sussman et al. 2011). For example, PDGF activates Akt in an IRS-independent manner in mouse embryonic fibroblasts, as we previously demonstrated (Guo et al. 2006).
We expect that the release of growth factors in the heart under different metabolic and mechanic conditions may provide additional mechanisms for activation of endogenous PI-3K and Akt and their compartmentation in cells. Understanding these factors involved in the complex pathophysiology may shed important insights in the dynamic changes of cardiac metabolism and adaptation. Evidently, a tightly controlled PI-3K and Akt by insulin and IGF-1 via IRS-1,-2 play central roles in governing myocardial metabolism and homeostasis, at least in the heart of male H-DKO mice, as we previously reported (Qi et al. 2013). In addition, similar to H-DKO mice, liver-specific IRS-1 and IRS-2 double genes knockout mice (L-DKO mice) also displayed mitochondrial dysfunction and liver damage, indicative as induction of mitochondrial fusion protein Mfn1 and reduction in mitochondrial electron transport chain complex III/IV and albumin gene expression; however, the mice survived over 12 months, rather than experiencing early death (Cheng et al. 2009, Guo et al. 2009). Taken together, these data suggest that different types of cells may tolerate the loss of Akt; therefore, insulin resistance may promote metabolic dysfunction and organ failure originating from various tissues. In this case, cardiomyocytes are more IRS-1,-2-dependent for survival than hepatocytes in mitochondrial function, insulin-stimulated glucose uptake and utilization and IRS-dependent cardiac structural maintenance for cardiac homeostasis.

Mora and coworkers demonstrated similar cardiac phenotype results with mice lacking cardiac phosphoinositide-dependent protein kinase-1 (PDK1) downstream from PI-3K, including dilated cardiomyopathy and death from heart failure (Mora et al. 2003). Thus, PDK1 is a critical upstream kinase for Akt activation by inducing phosphorylation at T308, whereas phosphoinositide-dependent protein kinase-2 (PDK2), a candidate which is not well known but likely to be mTOR complex 2 (mTORC2 or rictor-mTOR), partially activates Akt by inducing phosphorylation at S473 (Sarbassov et al. 2005, Guo 2014).

Critical roles of Akt in the heart

Protein kinase Akt has several downstream effectors, including mTOR complex 1 (mTORC1 or raptor mTOR) for protein synthesis and suppression of autophagy (Shirakabe et al. 2016), glucose transporter type 4 (Glut-4) for glucose uptake and forkhead box protein Foxo1 for control of gene transcription (Guo et al. 1999, Rena et al. 2013). Mice lacking the mTORC1 target p70S6K or Glut-4 were not significantly affected in cardiac growth and contractility (Abel et al. 1999, McMullen et al. 2004). However, recent studies demonstrated that mice lacking cardiac TORC1 displayed failure in embryonic heart development and growth (Zhang et al. 2010, Shende et al. 2011, Zhu et al. 2013). These animal models and data provide mechanistic insights on the role of endogenous Akt→TORC1 pathway in governing cardiac growth, metabolism and survival.

Akt activation not only stimulates protein synthesis and growth, but also integrates intracellular signaling into the nutrient metabolism, such as glucose oxidation and fatty acid synthesis, by promoting cell membrane translocation of Glut-4 and gene expression of glucokinase (Gck) and fatty acid synthase (Fasn). The levels of gene expression responsible for glucose utilization and lipid synthesis are significantly reduced in the absence of Akt activity in the cardiomyocytes lacking both IRS-1 and IRS-2 genes (Qi et al. 2013). In cardiomyocytes, IGF-1 enhances contractile function in a PI3K/Akt-dependent pathway that promotes Serca2a gene expression and Ca2+ handling (Kim et al. 2008).

Akt is known to be a survival player in promoting anabolic metabolism and suppressing autophagy and apoptosis (Shiojima et al. 2002, DeBosch et al. 2006). However, a constitutively prolonged activation of Akt in the heart is detrimental for cardiac remodeling (Matsui et al. 2002). We expect that catabolic metabolism and its counter regulation for insulin and Akt are required for the maintenance of cardiac function and homeostasis, such as autophagy. At the physiological level, the anabolic and catabolic metabolism are controlled by feeding and fasting conditions, respectively, by nutritional and hormonal regulation. An imbalance between anabolism and catabolism promotes diseases, such as cardiac hypertrophy or cachexia.

Cardiac Foxo1 signaling

The metabolic and survival regulation of Akt may partially depend on the Foxo1-mediated gene transcriptional programming. Foxo1 serves as an important regulator in suppressing glucokinase gene expression, limiting glucose oxidation and utilization in the heart and increasing autophagy (Liu et al. 2009, Battiprolu et al. 2012, Qi et al. 2013). Foxo1 stimulates cellular apoptosis by promoting gene expression of Bcl2 family members, such as Bim1 for caspase activation (Papanicolaou et al. 2008).
Overexpression of Foxo1 in the heart dose result in premature death in animals and aberrant expression is associated with cardiac failure in humans (Hannenhalli et al. 2006).

Cardiac protection is achieved by Foxo1 inactivation in rodents. Mice lacking Foxo1 in the heart displayed almost normal cardiac growth and function (Qi et al. 2015), and Foxo1 inactivation partially rescued cardiac dysfunction and death in mice lacking cardiac IRS-1 and IRS-2 (Qi et al. 2015), with similar results observed in db/db mice (Battiprolu et al. 2012). In particular, we demonstrated the key role of Foxo1 in stimulating cardiac dysfunction by promoting β-myosin heavy chain (β-MHC) gene expression, a myocardial structural gene responsible for reduction in cardiac contractility (Qi et al. 2015). Although diminished activity of Akt in animal hearts with T2D may enhance Foxo1-dependent gene expression responsible for atrophy, autophagy and apoptosis in many cells, which contribute to organopathy (Guo 2014), appropriate expression of Foxo1 promotes autophagy and anti-oxidative gene expression that is beneficial to the heart (Sengupta et al. 2009, 2011). We expect, however, hyperactivation of Foxo1 under pathological conditions is detrimental to health due to stimulation of cellular apoptosis. The complex interplay of various factors as well as the underlying mechanism involved in Foxo1 activation and heart failure require further investigation.

IRS-1 and IRS-2 are critical for adult cardiac homeostasis and function, via a suppression of Foxo1 or activation of mTORC1 downstream from PDK1 and Akt, evidenced by that suppression of IRS-1 and IRS-2 in adult heart caused Foxo1 activation, reduction in mTORC1 and cardiac dysfunction (Qi et al. 2015). During early embryogenesis, however, PDK1 activity is not required for the cardiac development (Mora et al. 2003). Similarly, Foxo1 is important for angiogenesis during vascular developmental stage but not necessary for the cardiac development (Hosaka et al. 2004, Qi et al. 2015). Overexpression of cardiac Foxo1 in mouse embryos prevents cell proliferation and heart development (Evans-Anderson et al. 2008). Taken together, these studies provide solid evidence that IRS and Foxo1 signaling are significant components for energy metabolism and organ survival in adult hearts and are mainly regulated by nutrients and hormones, such as insulin and IGF-1. We propose that IRS and Foxo1 serve as key mechanisms for maintaining cardiac energy homeostasis and survival by nutrients and endocrine systems, which are disrupted upon metabolic and mechanic stresses that occur under unhealthy conditions, such as diabetes, ischemia and mechanical overload.

**Cardiac insulin resistance, remodeling, p38α MAPK and heart failure**

Cardiac muscle requires either IRS-1 or IRS-2 for the maintenance of endogenous Akt activation and Foxo1 inactivation, thus promoting cardiac function and survival (Qi et al. 2013, Riehle et al. 2014). Both metabolic and mechanic stresses activate intracellular protein kinases that trigger serine or threonine phosphorylation of IRS proteins, which couple with IRS ubiquitination and degradation (Copps & White 2012). For example, insulin-induced mTORC1 activation triggers and promotes IRS-2 ubiquitination and degradation in fibroblasts (Guo et al. 2006). p38α MAPK (p38α) is another important protein kinase that is able to promote IRS-1 degradation and IRS-2 ubiquitination in cardiac myocytes (Qi et al. 2013).

Multiple protein kinase activation under metabolic stress and mechanic stretch shut down insulin action, thus restricting the anabolic metabolism. The heart employs protein kinase activation, which results in IRS degradation to deal with stresses so that anabolic metabolism is limited. Upon the hyperinsulinemia-induced metabolic stress, activation of p38α is necessary and sufficient for the induction of insulin resistance through suppression of IRS-1 and IRS-2 in cardiomyocytes (Qi et al. 2013) (Fig. 2). p38α is an important enzyme responsible for both pro-inflammatory factor TNFα and mechanic stretch signaling (Li et al. 2005, Hannenhalli et al. 2006). Activation of p38α promotes IRS-1 and IRS-2 degradation in cardiomyocytes upon metabolic stresses, such as hyperinsulinemia (Qi et al. 2013); thus, we propose that p38α may serve as a strong molecular link between insulin resistance and inflammation, and/or mechanic stretch, providing a powerful therapeutic target for improving myocardial dysfunction. The critical role of p38α in control of IRS-1 and IRS-2 stability in cardiomyocytes highlights the importance of future studies in assessing the regulatory system in humans. Furthermore, identifying the mechanisms of degradation of IRS-1 via Ser-636 and IRS-2 ubiquitination by p38 will enhance our understanding of the molecular basis of insulin resistance (Qi et al. 2013). Nonetheless, targeting the endogenous protein kinases, such as inhibitors of p38α, as blockers of IRS-1 and IRS-2 degradation, may eventually provide us effective interventions nutritionally and pharmaceutically for the treatment of diabetes and associated cardiovascular failure.
Fetal gene programming, energy metabolism and heart failure

Activation of fetal gene profiling is characteristic of cardiac remodeling and heart failure (Dirkx et al. 2013), including β-MHC, a Foxo1 target gene we have recently identified (Qi et al. 2015). Reprogramming of fetal gene expression was found in adverse cardiac remodeling and biomechanical stresses in failing or aging hearts (Marber et al. 2010, Koitabashi & Kass 2012). The transcriptional reprogramming in the cardiac remodeling may relate to a diminished cardiac insulin action followed by Foxo1 activation, as insulin resistance develops upon aging processes.

During the fetal development, nutrients from maternal supply are essential for growth and survival. In this stage, fetal gene expression is highly expressed in the presence of very low insulin levels; however, in the postnatal stage, insulin and IGF-1 become highly expressed and secreted from the pancreas and liver, respectively. They then play important roles in suppressing the expression of cardiac fetal gene programming, through activation of IRS-1,-2 and inhibition of cardiac Foxo1.

As aging progresses, insulin resistance gradually develops, the catabolic metabolism enhances and cardiac remodeling occurs. The Foxo1 inhibitory mechanism by insulin and IGF-1 becomes lost to some extent. Thus, we propose that the fetal gene programming is reactivated partly due to insulin resistance and Foxo1 activation (Qi et al. 2015). During early development of insulin resistance and T2D, when hyperinsulinemia from pancreas compensates for inefficient glucose uptake and utilization, it also suppresses fatty acid oxidation in myocardial mitochondria. Subsequently, when the intermediate of saturated fatty acids accumulates, such as ceramide derived from palmitate being a potent activator for p38α, it results in IRS degradation and Foxo1 activation. This activation stimulates cellular apoptosis or expression of genes, including heme oxygenase-1 (Hmox-1), a new target gene of Foxo1 degrading heme, an essential component for the electron transport chain of mitochondria, thus limiting mitochondrial biogenesis and function (Cheng et al. 2009).

When the mitochondrial function is reduced, incomplete glucose and lipid oxidation then activates other synthetic pathways, including pentose phosphate pathway (PPP), sorbitol and hexosamine biosynthetic pathways (HBP), which promote macromolecule synthesis and protein glycosylation that further stimulate cardiac hypertrophy followed by heart failure, often seen in rodents such as L-DKO and db/db mice, or patients with T2D (Qi et al. 2013). In the failing heart, energy deficiency is often indicated by reduction in ATP synthesis and activation of AMP-dependent protein kinase (AMPK) (Ji et al. 2013), an energy-deficient sensor that promotes beneficial glucose uptake and fatty acid oxidation for energy production (Zaha & Young 2012). All the processes are driven by mitochondrial dysfunction that controls ATP production, reactive oxygen species (ROS) generation and induction of cellular apoptosis. Taken together, we believe that targeting mitochondrial biogenesis and metabolism would provide a powerful strategy to prevent or treat heart failure in the future.

Crosstalk between insulin signaling and renin–angiotensin system via Foxo1

Currently, the first line of clinical treatment for the patients with heart failure is the blocker for the renin–angiotensin system or the β-adrenergic receptors (Koitabashi & Kass 2012). Insulin protects the heart and reduces blood pressure (Anderson et al. 1991). In recent years, we have established a potential molecular link between insulin and angiotensin signaling (Qi et al. 2014). By identifying that Foxo1 targets and stimulates gene expression of angiotensinogen, a precursor of peptide hormone angiotensin II (Ang II), which promotes cardiovascular constriction, we demonstrated that insulin reduces blood pressure through suppression of Foxo1-mediated angiotensinogen gene expression and production of Ang II (Qi et al. 2014).

Angiotensinogen is largely expressed in the liver and in the adipose tissue particularly in obese populations (Yiannikouris et al. 2012). The components of renin–angiotensin signaling are also minimally expressed in the heart and enhanced by hyperglycemia, which promotes myocardial death and diabetic cardiomyopathy (Singh et al. 2008). Targeting the intracellular renin–angiotensin system achieved beneficial effect on cardiac protection in type1 diabetes mellitus and hyperglycemia-induced cardiac dysfunction (Kumar et al. 2012). Taken together, with the elevated gene expression of angiotensinogen by hyperglycemia, existence of intracellular angiotensin system in various tissues, expansion of adipose tissue and elevated blood pressure of animals with obesity and T2D (Su et al. 2008, Yiannikouris et al. 2012), we expect that failure of suppression of angiotensinogen for the production of Ang II by insulin resistance may have a significant impact.
on the development of hypertension and associated cardiovascular dysfunction in humans.

**Crosstalk between insulin signaling and β-adrenergic receptor signaling via IRS**

Increased catecholamine release, including epinephrine and norepinephrine, stimulates the sympathetic nervous system (SNS) and promotes heart failure (Bristow 2011). Binding of catecholamine to the cardiac β1-adrenergic receptor (β1-AR, mainly) and β2-adrenergic receptor (β2-AR, to a lesser extent), two family members of G-protein-coupled receptors (GPCRs), stimulates cardiac rate and contractility by largely activating Gs proteins (stimulatory proteins) when bound to guanosine diphosphate (GTP). Gs proteins stimulate the effector adenylate cyclase, which converts ATP to the second messenger adenosine 3′,5′-monophosphate (cAMP) and activates the cAMP-dependent protein kinase A (PKA). PKA is the major effector of cAMP and phosphorylates a variety of substrates in control of myocardial Ca²⁺ handling and contractility under physiological conditions (Fig. 3). In heart failure pathogenesis, elevated SNS activation and subsequent catecholamine overdrive via β-AR stimulation was initially an adaptive mechanism to compensate for decreased heart rate and cardiac contractility.

![Diagram of crosstalk between insulin/IGF-1 signaling and β-adrenergic receptor signaling](image-url)

**Figure 3**

Crosstalk between insulin/IGF-1 signaling and β-adrenergic receptor signaling in control of cardiac catabolism and anabolism via the GRK2. Binding of catecholamine agonists to the G-protein-coupled receptor (GPCR) that has seven transmembrane domains produces a conformational change in the GPCR, which promotes the binding of G-protein to the intracellular-binding site on the receptor. The G-protein is heterotrimeric and activated Gα and Gβγ subunits are responsible for the activation of specific effectors, which produce different second messengers that generate a wide range of cellular responses, particularly for Ca²⁺ handling, cardiac contractility, catabolism and apoptosis. The desensitization of GPCR is triggered by interaction with GRK-2 that phosphorylates the β-AR and enhances its interaction with β-arrestin. GRK-2 also activates PDE-4D gene expression by activating MAPK, thus suppressing cAMP production and PKA activity. An increase in receptor affinity toward β-arrestin for Gα protein uncoupling to Gβγ subunit arrests the signal propagation. It is expected that GRK-2 may interact and phosphorylate IRS-1 and IRS-2, desensitizing insulin/IGF-1 signaling in the activation of PI-3K and Akt for control of anabolism and survival. β, G-protein β subunit; γ, G-protein γ subunit; AC, adenylate cyclase; cAMP, cyclic 3′,5′-adenosine monophosphate; Gα, G-protein α subunit; GRK-2, G-protein coupled receptor kinase-2; PDE-4D, phosphodiesterase 4D.
and to maintain mean arterial pressure; however, it eventually maladapted to promote disease progression, including myocardial ischemia, pathologic hypertrophy, arrhythmogenicity, myocardial fibrosis, necrosis and apoptosis (Lymperopoulos et al. 2013, Zhang et al. 2013). This maladaptive response results partially from downregulation and desensitization of cardiac β-ARs due to chronic catecholamine stimulation. In the failing hearts, excess catecholamine on β-AR stimulation induces selective downregulation of β1-AR and alters the ratio of β1-AR to β2-AR from an 80:20 distribution to a ratio of 60:40 and both β1-AR and β2-AR in failing hearts prevail in a desensitized condition (Rudomanova & Blaxall 2017). Recent studies demonstrated that β-AR desensitization is largely mediated by the G-protein-coupled receptor kinase 2 (GRK-2) that is highly expressed in the failing heart. Phosphorylation of serine or threonine residues of β-AR in turn recruits β-arrestin 2, leading to the uncoupling Gα with Gβγ and arresting signaling propagation for cardiac contractile function. This also serves as a new and important mechanism by which β-AR signaling is suppressed or desensitized and its role in promoting heart failure (Rudomanova & Blaxall 2017).

Fu and coworkers reported that insulin suppresses catecholamine-induced cAMP elevation and PKA activation in cardiomyocytes in an IRS-1 or IRS-2-dependent manner, and insulin inhibits cardiac contractility by inducing Gi (inhibitory proteins)-based β2-AR (Fu et al. 2014). Moreover, insulin promotes cAMP degradation by inducing the expression of gene encoding phosphodiesterase-4D (PDE-4D), a process that requires MAPK activation involving the stimulation of GRK-2 and interaction of β2-AR and arrestin 2, which is active in high-fat diet-induced insulin-resistant heart. However, inhibiting GRK-2 by small compounds, such as paroxetine, significantly suppresses insulin-mediated MAPK activation and PDE-4D induction, restoring the β-AR action and preventing diabetes-related cardiac contractile dysfunction (Wang et al. 2017).

Considering the enhanced GRK-2 in insulin-resistant or failing heart, we predict that GRK-2 may serve as a protein kinase to target IRS-1 and IRS-2 serine/threonine phosphorylation in promoting insulin resistance, even though the mechanism has not yet been established and potential phosphorylation residues of IRS-1,-2 by GRK-2 still need further identification. Indeed, deletion of half the amount of GRK-2 gene expression systemically in mice protected against high-fat diet (HFD)-induced insulin resistance and obesity (Garcia-Guerra et al. 2010), as well as enhanced cardiac insulin-stimulated Akt phosphorylation and glut-4 membrane translocation and reduced cardiac steatosis and fibrosis (Lucas et al. 2014, 2016). By contrast, overexpression of GRK2 in cardiomyocytes attenuated insulin-induced Akt phosphorylation and glut-4 membrane translocation (Ciccarelli et al. 2011). In 3T3-L1 adipocytes, it was shown that the regulator of G-protein signaling (RGS) domain that interacts with Gq/11 in GRK2 is required for insulin inhibition on glucose transport (Usui et al. 2004). Thus, GRK-2 is a negative regulator of insulin signaling. A unified pathway that merges IRS signaling to β-AR signaling via GRK-2 was proposed in Fig. 3. Recent studies showed that insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (Smooke et al. 2005), in which hyperinsulinemia and its induction of Gi-based β2-AR can promote cardiac dysfunction and failure (Zhu et al. 2012). Our recent study in cardiomyocytes demonstrated that chronic excess insulin stimulation desensitizes insulin signaling for Akt activation by suppressing IRS-1 and IRS-2, which likely occurs in HFD-induced insulin-resistant heart via p38α activation. Alternatively, the cardiac suppression of IRS-1 and IRS-2 in HFD-treated mice may also relate to GRK-2 upregulation that promotes IRS serine/threonine phosphorylation and protein degradation, desensitizing both insulin signaling for Akt activation and β-AR signaling for PKA activation, which results in cardiac contractile dysfunction under conditions of hyperinsulinemia and excess catecholamine stimulation during diabetes and heart failure development.

**Obesity paradox in heart failure**

Studies in humans and animal models have revealed that heart failure is highly associated with generalized insulin resistance (Velez et al. 2014, Riehle & Abel 2016). However, recent studies have reported a significant increase in survival rates of obese individuals in the context of heart failure, leading to the unexpected phenomenon known as the ‘obesity paradox’ (Lavie et al. 2013). An underlying reason involves cardiac cachexia with a poor heart failure prognosis and in the promotion of catabolic metabolism. This condition is counteracted by the effect of obesity that would adversely affect cachexia and promote the anabolic metabolism and survival despite the role of the heart in metabolic stresses. Furthermore, hormones and cytokines secreted from expansion of adipose tissues in obese individuals may offer positive cardio-protective actions although such factors have yet to be identified. Under insulin-resistant conditions, such as in the case of
HFD-fed mice, hyperinsulinemia activates endogenous MAPK pathway that suppresses catecholamine-induced cAMP and PKA signaling in promoting a dual role in control of cardiac contractility and apoptosis, to some extent, depending on the cellular context, therefore explaining the paradox of hyperinsulinemia and obesity on the cardiac function (Fig. 3). Overall, we expect that heart failure occurs through the gradual suppression of Akt signaling and increase of catecholamine-induced cAMP production and highly activated PKA for induction of apoptosis during heart failure development. Eventually, cAMP-induced PKA activation can be largely suppressed at a later phase of heart failure, indicative as an induction of cardiac contractile dysfunction, GRK2 activation and desensitization of the β-AR function (Figs 3 and 4).

**Conclusions and prospects**

Akt inactivation and Foxo1 activation after suppression of IRS-1 and IRS-2 provide a fundamental mechanism for cardiac insulin resistance, activation of MAPK and elevation of the renin–angiotensin signaling cascade, which are present in many pathological conditions. The regulatory mechanisms of IRS→Akt→Foxo1 cascades and their interactions with other signaling cascades, such as β-AR signaling, should be further explored under different cellular and environmental contexts, including ischemia, hypertrophy and malnutrition. Targeting IRS-1 and IRS-2 by activating the Akt→Foxo1 signaling cascade and associated protein kinases and target genes will be critical for the prevention and treatment of diabetes and associated cardiac dysfunction in the future.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

**Funding**

Dr Shaodong Guo’s research is supported by grants from the American Diabetes Association Career Development Award (1-15-CD-09) and
remodeling in heart. *Circulation* 111 2494–2502. (doi:10.1161/01.\_CIR.0000165117.71483.OC)


Received in final form 29 March 2017
Accepted 5 April 2017
Accepted Preprint published online 5 April 2017